ASC30_48_39FDC

ASC30_48_39FDC is a discovery-stage, small molecule triple agonist fixed-dose combination (FDC) developed by Ascletis (歌礼生物科技) for the treatment of obesity. The drug acts as a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), the gastric inhibitory polypeptide receptor (GIPR), and the amylin receptor (specifically the SARA variant). By combining these three mechanisms, the drug aims to leverage synergistic effects on appetite suppression, glucose metabolism, and weight loss. As a small molecule FDC, it is designed to potentially offer oral bioavailability, providing a more convenient alternative to injectable peptide-based incretin therapies currently in development.